Boehringer Ingelheim announced today that the FIBRONEERâ„¢-ILD trial met its primary endpoint, which was the absolute change from baseline in forced vital capacity (FVC) [mL] at week 52 versus placebo.
Xona Systems, a leading provider of secure access management solutions for critical infrastructure, today announced the integration of the Xona Platform with the Nozomi Networks Arc Endpoint Sensor, ...
Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine. New Drug Application (NDA) Submission Expected in the ...
In today's digital landscape, data processing can occur either at centralized locations like data centers and on-premise ...
In this business solutions, Discover the key cybersecurity trends and threats shaping India in 2025, learn how businesses and ...
Why does the Secure Framework Matter? The focus of this operation isn’t just about the immediate prevention of potential threats but ensuring we have a solid line of defense that could weather any ...
BeyondTrust is leading the charge in transforming identity security to prevent breaches and limit the blast radius of attacks, while creating a superior customer experience and operational ...
Robert Haist tells Infosecurity about TeamViewer’s response and learnings after being attacked by Russian nation-state actor ...
The recent executive order banning paper straws in the United States marks a pivotal shift in sustainability policy. While well-intentioned, the push for alternatives like Paper Pulp and new chemistry ...
Europe logistic projects since the Chinese Belt Road. Ukraine and Italy will play a part in the India-Middle ...
A Radical New Approach to Resolving the Arab-Israel Conflict. In early 2014, I hiked the Israel National Trail, an 800-mile ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback